Trial Profile
A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs GLPG 1205 (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Proof of concept; Therapeutic Use
- Acronyms PINTA
- Sponsors Galapagos NV
- 03 Nov 2022 Results assessing efficacy, safety, and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis published in the European Respiratory Journal
- 30 Nov 2020 According to a Galapagos NV media release, full results from this study will be submitted to a future medical conference and peer-reviewed medical journals.
- 30 Nov 2020 Top-line results published in the Media Release